A PHASE II, OPEN-LABEL, MULTICENTER,
RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF RO7198457 IN COMBINATION WITH PEMBROLIZUMAB VERSUS PEMBROLIZUMAB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED MELANOMA
The purpose of the study is to compare the effects, good or bad, of RO7198457, a personalized cancer vaccine (hereafter referred to as the study drug) plus pembrolizumab versus pembrolizumab alone in participants with melanoma. We are hoping to find out if the combination of the study drug and pembrolizumab is a safe and effective way to treat melanoma compared to pembrolizumab alone.
untreated unresectable locally advanced or metastatic melanoma
Male and Female participants of 18 years of age and older.
unresectable locally advanced (Stages IIIC and IIID) and metastatic (recurrent or de novo Stage IV) melanoma.
18 - 100
Healthy Volunteers Needed
Duration of Participation
If you are determined to be eligible for the study, you will receive the study drugs for up to 2 years or until your disease worsens, you experience unacceptable side effects, or you withdraw your consent to participate in the study.
After you finish the study intervention, the investigator will continue to watch you for side effects and follow your condition every 3 months for indefinitely through a telephone phone call or a clinic visit.
Knight Clinical Trials Information Line